西安国际医学投资股份有限公司投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 业绩说明会  | | 投资者关系活动 | □新闻发布会 路演活动 | | 类别 | 现场参观 | | | 其他_____ | | 参与单位名称及 | 天风证券杨松、李慧瑶、师静秋、张静怡，开源证券蔡明子、古意涵、牛 | | 人员姓名 | 筱梦，中信证券陈竹，广发证券方程嫣、王少喆、刘新玮，兴业证券东楠、 | | | 何斯源，国盛证券胡婧怡、宋歌，东吴证券冉胜男、李倩，中信建投证券 | | | 王在存、吴严、刘岚，中金公司张一弛、李千翊、梁振霆，西南证券申江、 | | | 王钰畅、李根林，东北证券刘宇腾、叶菁、刘新元，华西证券程仲瑶，民 | | | 生证券乐妍希，华安证券谭国超、陈珈蔚、冯世骄，华创证券王港、王宏 | | | 雨，信达证券唐爱金、朱丁宁、杨博，德邦证券刘闯、王宣宇、许家成、 | | | 郭小倩，东海证券杜永宏、伍可心，安信证券贺鑫，光大证券吴佳青，海 | | | 通证券梁广锴、陈铭，华泰证券孙茗馨，上海证券徐昕，申万宏源证券余 | | | 玉君，万和 ...

公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司在本报告第三节" 管理层讨论与分析" 中" 十、公司面临的风险 和应对措施 "部分，详细描述了公司经营中可能存在的风险及应对措施，敬 请投资者关注相关内容。 目 录 备查文件目录 2、载有公司法定代表人、财务总监、会计机构负责人签名并盖章的财务报告文本； 西安国际医学投资股份有限公司 3 | --- | --- | --- | |--------------------------------------|-------|--------------------------------------------------------| | 释义项 | 指 | 释义内容 | | 证监会、中国证监会 | 指 | 中国证券监督管理委员会 | | 国家、陕西省、西安市卫健委 | 指 | 国家、陕西省、西安市卫生健康委员会 | | 深交所 | 指 | 深圳证券交易所 | | 公司、本公司、集团、本集团、国际医学 | 指 | 西安国际医学投资股份有限公司 | | ...

中服务供给的不足，满足业务发展的需要。 3、二季度的营业情况如何呢？能够继续缩小亏损空间吗？ 感谢您的关注，伴随着国内经济的复苏，对医疗服务行业阶 段性不利影响逐渐消除，市场环境稳定向好，2023 年一季度公 司实现营业收入 10.59 亿元，同比增长 247%，单季度营收创 2019 年以来新高，一季度归母净利润-7,474 万元，同比大幅减亏 82.55%。公司 2023 年一季度的经营成效为公司加快发展开启了 新阶段，进入二季度以来，公司经营稳健，各项工作扎实推进， 有关公司第二季度的具体业绩情况，公司将按照信息披露的有关 要求，在 2023 年半年度报告中详尽披露。 证券代码： 000516 证券简称：国际医学 编号：2023-03 西安国际医学投资股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | | 新闻发布会 路演活动 □ □ | | | | 现场参观 □ | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 ...

证券代码：000516 证券简称：国际医学 编号：2023-02 西安国际医学投资股份有限公司投资者关系活动记录表 | | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 | | --- | --- | | |  | | 投资者关系活动 | □新闻发布会 路演活动 | | 类别 | 现场参观 | | | 其他_____ | | 参与单位名称及 | 天风证券杨松、李慧瑶，中信证券沈睦钧、张佳绘，国盛证券胡偌碧、王 | | 人员姓名 | 光华、宋歌、胡婧怡、齐德仪，兴业证券东楠，开源证券蔡明子、古意涵， | | | 申万宏源证券张静含、余玉君、陈田甜，广发证券陈明、王少喆、方程嫣， | | | 东北证券刘宇腾、叶菁、孙维泽，海通证券梁广楷，西部证券陆伏崴、陈 | | | 嘉烨，中信建投证券刘岚，安信证券贺鑫、马正南，光大证券刘勇、吴佳 | | | 青，东吴证券冉胜男，国都证券文惠霞，华安证券谭国超、陈珈蔚，平安 | | | 证券李颖睿，国信证券李茗欣、贺平鸽，国联证券安柯，国融宗楚昀，东 | | | 兴证券刘春胜，东亚前海证券孙洁玲、都成，华泰证券孙茗馨，首创证券 | | | 陈宇，华金证券周平、吴 ...

Financial Performance - Total assets increased by 1.48% to RMB 13,460,535,622.49 compared to the adjusted figure of RMB 13,264,224,493.51[6] - Equity attributable to shareholders of the listed company decreased by 1.55% to RMB 4,184,794,966.92 from the adjusted figure of RMB 4,250,695,185.16[6] - Net profit for the period was RMB -95,739,550.26, compared to RMB -432,820,830.09 in the same period last year[10] - Diluted earnings per share were RMB -0.0291, compared to RMB -0.1882 in the same period last year[10] - The company achieved a revenue of 1,059.09 million yuan in Q1 2023, a year-on-year increase of 247.40%[22] - Net profit attributable to the parent company in Q1 2023 was -74.74 million yuan, a year-on-year increase of 82.55%[22] - Total operating revenue for the current period is RMB 1,059,092,457.42, a significant increase from RMB 304,865,465.75 in the previous period[30] - Net profit attributable to the parent company's owners is RMB -74,740,547.17, compared to RMB -428,421,595.49 in the previous period[45] - Basic earnings per share for the current period is RMB -0.0328, an improvement from RMB -0.1882 in the previous period[45] - Revenue for the reporting period was 1,059,092,457.42 yuan, a 247.40% increase year-over-year[52] - Net profit attributable to shareholders improved to -74,740,547.17 yuan, an 82.55% improvement compared to the same period last year[52] - Basic earnings per share improved to -0.0328 yuan, an 82.57% increase compared to the same period last year[52] - Weighted average return on equity improved to -1.75%, a 6.59 percentage point increase from the same period last year[52] Operating Costs and Expenses - Operating costs increased by 78.92% year-on-year due to the new medical campuses and business expansion of the medical subsidiaries[9] - Taxes and surcharges increased by 151.05% year-on-year, mainly due to increased property tax provisions by the subsidiary Xi'an International Medical Center Co., Ltd.[9] - Operating costs for the current period are RMB 972,385,400.75, up from RMB 543,474,761.78 in the previous period[30] - R&D expenses for the current period are RMB 3,325,497.80, up from RMB 2,358,282.37 in the previous period[30] - Taxes and fees paid increased to 17,689,687.01 yuan, up from 12,038,564.57 yuan in the same period last year[47] - Employee compensation and benefits paid were 398,160,903.03 yuan, slightly higher than the previous year's 392,733,192.48 yuan[47] Cash Flow - Net cash flow from operating activities increased by 208.07% year-on-year due to significant revenue growth from medical subsidiaries[9] - Net cash flow from financing activities increased by 565.41% year-on-year due to increased cash received from loans by the company and its subsidiaries[9] - Cash received from selling goods and providing services is RMB 804,974,363.77, up from RMB 350,233,145.31 in the previous period[45] - Operating cash flow increased significantly to 222,931,373.21 yuan, a 208.07% increase compared to the same period last year[52] - Net cash flow from financing activities was 130,029,914.30 yuan, compared to -27,939,026.41 yuan in the same period last year[48] - Cash and cash equivalents decreased by 2,154,077.89 yuan, ending the period at 1,181,624,032.36 yuan[48] - Investment cash outflow was 379,185,244.06 yuan, primarily for fixed assets and long-term investments[47] Asset and Liability Changes - Accounts receivable increased by 39.85% compared to the end of the previous year, mainly due to increased medical insurance settlement receivables[22] - Prepayments increased by 151.28% compared to the end of the previous year, mainly due to increased prepaid operating expenses[22] - Other current assets increased by 30.35% compared to the end of the previous year, mainly due to increased deductible input tax[22] - Fixed assets increased by 40.49% compared to the end of the previous year, while construction in progress decreased by 96.34%, mainly due to the transfer of completed projects to fixed assets[22] - Other non-current assets increased by 32.50% compared to the end of the previous year, mainly due to increased prepayments for equipment[22] - Minority interests decreased by 17,655.36% compared to the end of the previous year, mainly due to reduced minority interest losses[22] - Total current liabilities amounted to 5,744.59 million yuan, while total non-current liabilities amounted to 3,552.03 million yuan[15] - Total liabilities and owner's equity amounted to 13,460.54 million yuan[15] - Total assets at the end of the period are RMB 13,460,535,622.49, slightly higher than RMB 13,264,224,493.51 at the beginning of the period[41] - Fixed assets at the end of the period are RMB 7,986,846,562.55, a significant increase from RMB 5,684,908,536.84 at the beginning of the period[41] - Total current assets at the end of the period are RMB 3,915,116,034.38, compared to RMB 3,711,899,394.23 at the beginning of the period[41] - Total non-current assets at the end of the period are RMB 9,545,419,588.11, slightly lower than RMB 9,552,325,099.28 at the beginning of the period[41] Investment and Fair Value Changes - Investment income decreased by 98.30% year-on-year due to reduced financial product income[9] - Fair value change income increased by 210.03% year-on-year due to increased fair value change income from held trading financial assets[9]

Corporate Governance - The company held its annual general meeting on May 18, 2022, with a participation rate of 43.21%[6] - The first extraordinary general meeting of 2022 was held on September 23, 2022, with a participation rate of 46.50%[6] - The company has established a sound organizational structure, ensuring independent operation of the shareholders' meeting, board of directors, supervisory board, and management[5] - The company strictly adheres to laws and regulations regarding information disclosure, ensuring all shareholders have equal access to information[2] - The company’s governance practices align with legal and regulatory requirements, showing no significant discrepancies[3] - The company’s supervisory board has not raised any objections regarding the supervision matters during the reporting period[21] - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements for decision-making[38] - The company is committed to improving its governance structure in compliance with relevant laws and regulations, ensuring transparency and protecting shareholder rights[98] - The company has established a comprehensive governance structure and internal control system to enhance operational efficiency and management capabilities[178] Employee Management and Development - The company has implemented a restricted stock incentive plan to attract and retain talent, approved on April 12, 2021[26] - The company emphasizes employee training, combining internal and external training methods to enhance staff capabilities[24] - The company has implemented a performance evaluation system for senior and middle management, linking compensation and promotions to performance metrics[40] - The remuneration for directors and senior management is determined based on the approved compensation plan, with 18 individuals receiving salaries during the reporting period[44] - The company encourages employee feedback on management practices, which is considered in the evaluation of outstanding employees[40] - The company has introduced 560 new personnel, including 19 PhDs and 67 Master's degree holders, enhancing its talent pool[186] - The company has a robust talent management system, attracting and nurturing a team of experienced medical professionals, which is crucial for its long-term growth[199] Financial Performance - The company's operating revenue for 2022 was approximately ¥2.71 billion, a decrease of 7.19% compared to the previous year[135] - The net profit attributable to shareholders for 2022 was approximately -¥1.18 billion, representing a decline of 43.12% year-over-year[135] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥1.12 billion, a decrease of 49.44% compared to the previous year[135] - The net cash flow from operating activities for 2022 was approximately ¥461.34 million, an increase of 1.10% year-over-year[135] - The total assets at the end of 2022 were approximately ¥13.26 billion, a slight decrease of 0.42% from ¥13.32 billion in 2021[156] - The net assets attributable to shareholders decreased by 20.18% to approximately ¥4.25 billion from ¥5.33 billion in 2021[156] - In 2022, the company reported a non-operating loss of approximately 53.95 million, an improvement from a loss of 70.89 million in 2021[159] - The company’s non-current asset disposal profit was approximately 8.46 million in 2022, compared to a loss of 0.21 million in 2021[159] - The government subsidies recognized in the current period amounted to approximately 9.04 million, an increase from 8.38 million in 2021[159] - The company’s investment management losses decreased significantly to approximately 17.02 million in 2022 from 39.67 million in 2021[159] Business Strategy and Development - The company aims to enhance its core competitiveness by accelerating the construction of new medical projects and improving overall medical service levels[72] - The company is focusing on expanding its medical services business, which is considered the main direction for future development[72] - The company has a talent strategy in place, aiming to attract high-level medical professionals to support its rapid business expansion[71] - The company is advancing its digital transformation strategy by establishing a cloud-based medical information service system to optimize hospital operations and improve patient experience[93] - The company is focusing on integrating artificial intelligence technologies in healthcare, exploring applications such as AI-assisted clinical decision-making and personalized medical advice[95] - The company is expanding its business layout and optimizing operational efficiency through strategic mergers and acquisitions[96] - The company is actively promoting the development of specialty departments and improving service quality to achieve rapid growth in medical services[92] - The company is expanding its medical services by constructing the North Campus of Xi'an International Medical Center Hospital, which will include ten specialized hospitals and is set to enhance service capacity significantly[156] - The company is developing a proton therapy center, which will be the first of its kind in Northwest China, enhancing its capabilities in cancer treatment[173] - The company is actively participating in the healthcare reform policies that encourage private investment in medical services, aiming to improve resource allocation and service quality[163] - The company is leveraging policy opportunities to benefit its medical business, particularly in rehabilitation and assisted reproductive services, in response to increasing demand due to aging population and supportive government policies[190] Quality and Risk Management - The company maintains a profit distribution policy with no changes during the reporting period, with independent directors reviewing the distribution plan[23] - The company has a complete asset independence, with no instances of the controlling shareholder occupying or controlling company assets[4] - The internal control system has been established to ensure effective risk management and operational efficiency, covering 73.31% of total assets and 96.19% of total revenue[37] - The company has a comprehensive internal control mechanism that is continuously optimized to mitigate operational risks[35] - The company emphasizes the importance of internal control and risk management to mitigate operational risks[72] - The company is committed to integrating advanced medical technologies and practices to improve its service offerings and operational efficiency[196] - The company is implementing a quality management system to ensure high standards of patient care and safety across its facilities[91] Market Position and Growth - The total market size of China's consumer medical services in 2022 was approximately ¥1.26 trillion, expected to grow to ¥2.39 trillion by 2025, with a CAGR of 23.78%[142] - The company has established a comprehensive medical service platform, becoming one of the large medical health management groups in China[146] - The company signed a partnership with Mayo Clinic, enhancing its medical services to align with international standards[147] - The company is positioned to benefit from favorable national policies supporting the development of social medical services[145] - The company anticipates rapid recovery and sustained growth in its business due to improving external macroeconomic conditions[143] - The company is expanding its market presence in the central and western regions of China, aiming to establish a comprehensive healthcare network[196] - The company has developed a large-scale medical service group with 10,000 beds, becoming a benchmark enterprise in China's capital market for comprehensive medical services[176] Social Responsibility and Community Engagement - The company is committed to social responsibility, including support for impoverished patients and emergency medical services[67] - The company will actively promote ESG initiatives and integrate ESG factors into daily management, aiming for sustainable development[103] - The company has been recognized with multiple awards, including the "Shaanxi Medical Health Science Popularization Innovation Award" and "Shaanxi Medical Patient Satisfaction Innovation Service Award" in 2022[156] - The company is actively expanding its tiered medical service system by establishing community health service centers and collaborating with over 100 grassroots medical institutions in Shaanxi province[196] - The company emphasizes improving service quality and patient satisfaction through a 24-hour one-stop service center[104]

Financial Performance - The company's operating revenue for Q3 2022 was ¥845,876,573.04, representing a 13.96% increase year-over-year[3] - The net profit attributable to shareholders was -¥231,362,028.34, a decrease of 2.81% compared to the same period last year[3] - The net profit for Q3 2022 was -845,567,027.07 CNY, compared to -594,151,455.04 CNY in the same period last year, indicating a significant increase in losses[16] - Operating profit for Q3 2022 was -844,797,210.13 CNY, worsening from -573,099,834.99 CNY year-over-year[16] - The company reported a total comprehensive loss of -845,567,027.07 CNY for the period, compared to -594,151,455.04 CNY last year[17] - Basic and diluted earnings per share were both -0.3634 CNY, worsening from -0.2641 CNY in the previous year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥2,803,634.80, reflecting a significant decrease of 101.76% year-over-year[3] - Net cash flow from operating activities was -2,803,634.80, a significant decrease from 159,391,376.23 in the previous period[19] - Total cash inflow from investment activities was 1,049,534,736.13, down from 2,641,357,872.76 in the prior period[19] - Cash outflow from investment activities totaled 1,618,157,380.48, compared to 4,414,384,950.21 previously, resulting in a net cash flow of -568,622,644.35[19] - Cash inflow from financing activities was 777,619,600.00, a decrease from 2,120,819,899.01 in the last period[19] - Net cash flow from financing activities was 46,620,668.65, down from 1,389,095,808.94 in the previous period[19] - The ending cash and cash equivalents balance was 994,285,889.98, compared to 734,933,499.02 at the end of the previous period[19] - Cash outflow for employee payments increased to 979,061,713.60 from 848,032,985.04[19] - Total cash outflow from operating activities was 2,115,497,127.13, compared to 1,860,771,343.41 previously[19] - Cash inflow from recovering investments was 944,973,491.64, down from 2,500,370,058.84 in the prior period[19] - The company received tax refunds totaling 203,665,328.19 during the reporting period[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥12,661,602,703.85, down 4.94% from the end of the previous year[3] - The equity attributable to shareholders decreased by 12.37% to ¥4,666,779,589.77 compared to the end of the previous year[3] - Total liabilities amounted to CNY 7,999,659,442.52, slightly up from CNY 7,988,793,342.79 in the previous year[15] - The company's total assets decreased to CNY 12,661,602,703.85 from CNY 13,320,275,545.11 year-over-year[15] - Short-term borrowings increased significantly to CNY 614,643,609.69 from CNY 225,840,472.52, marking a 172.00% rise[15] - Non-current liabilities totaled CNY 4,370,349,428.12, down from CNY 4,493,206,560.09 in the previous year[15] - The company's equity attributable to shareholders decreased to CNY 4,666,779,589.77 from CNY 5,325,517,348.40 year-over-year[15] - Current assets totaled CNY 1,738,524,326.06, down 25.41% from CNY 2,331,003,303.45 year-over-year[14] - Accounts receivable rose to CNY 460,919,638.02, an increase of 26.00% compared to CNY 365,883,073.06 in the previous year[14] - Inventory decreased slightly to CNY 81,313,262.03 from CNY 84,077,981.90, a decline of 3.25%[14] Strategic Initiatives - The company signed a strategic cooperation agreement with Wenzhou Medical University on August 12, 2022, to enhance clinical teaching and medical talent training[10] - The company aims to establish a high-level talent training base and a high-quality medical service demonstration base through its collaboration with Wenzhou Medical University[10] - The strategic partnership with Wenzhou Medical University is expected to foster academic exchanges and resource sharing in medical research and public health[10] - The company approved a restricted stock incentive plan for 138 core technical and management personnel, granting up to 7,662,313 shares, with performance targets set for revenue growth rates of 80%, 85%, and 165% for the years 2021, 2022, and 2023 respectively[11] - The company’s performance assessment indicators for the incentive plan were adjusted due to the impact of COVID-19 on its medical services[11] - The company is focused on optimizing its business structure and enhancing its comprehensive strength through new specialized services[12] Expenses - Total operating costs increased to CNY 2,713,905,628.44, up 6.29% from CNY 2,553,360,139.15 in Q3 2021[15] - Research and development expenses increased to 9,456,290.06 CNY from 7,511,041.98 CNY, reflecting a 26% rise[16] - Financial expenses rose to 138,903,846.53 CNY, up from 119,817,441.59 CNY, marking a 16% increase[16] - The tax expenses for the quarter were 370,551.10 CNY, significantly lower than 11,264,337.76 CNY in the same quarter last year[16] - The company experienced a foreign exchange loss of -62,560,971.84 CNY, an improvement from -91,060,283.16 CNY in the previous year[16] - Non-recurring losses totaled -¥22,524,596.85 for the current period, with significant impacts from fair value changes of financial assets[4] - The company recorded a net investment loss of 11,533,305.25 CNY, down from 18,606,940.38 CNY year-over-year[16]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,068,020,568.30, a decrease of 18.24% compared to ¥1,306,357,492.07 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was -¥595,727,097.49, representing a decline of 65.53% from -¥359,887,683.38 in the previous year[13]. - The net cash flow from operating activities was -¥202,563,296.94, a significant decrease of 360.53% compared to ¥77,749,454.50 in the same period last year[13]. - The basic earnings per share were -¥0.2618, down 59.15% from -¥0.1645 in the previous year[13]. - Total assets at the end of the reporting period were ¥12,936,387,641.57, a decrease of 2.88% from ¥13,320,275,545.11 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company were ¥4,878,411,430.73, down 8.40% from ¥5,325,517,348.40 at the end of the previous year[13]. - The company reported a significant increase in non-recurring losses, totaling -¥17,045,067.39 for the reporting period[15]. - The weighted average return on net assets was -11.75%, a decline of 5.39% compared to -6.36% in the previous year[13]. - The company reported a significant decrease in cash and cash equivalents, with a net decrease of ¥634,096,192.74, down 142.47% from ¥1,493,014,393.17[53]. - The operating cost increased by 2.64% to ¥1,263,238,875.72 from ¥1,230,784,487.52[53]. - The company reported a significant reduction in investment income, with a loss of ¥33,356,507.97 from fair value changes in financial assets[57]. Operational Highlights - The company provided outpatient services to 858,300 patients and inpatient services to 43,700 patients during the reporting period[19]. - The Xi'an High-tech Hospital achieved operating revenue of 376 million yuan in the first half of 2022, down 30.06% year-on-year, with a net profit of -86 million yuan, a decrease of 302.17% year-on-year[20]. - The Xi'an International Medical Center Hospital provided outpatient services to 201,600 patients and inpatient services to 24,800 patients in the first half of 2022, with a peak daily inpatient count of 2,270 beds post-resumption[23]. - The company reported a significant increase in service volume post-resumption, with outpatient services in Q2 reaching 533,000 patients, a 1,066.59% increase compared to Q1[22]. - The company has established partnerships with 4 tertiary hospitals, 22 secondary hospitals, and 28 grassroots medical units in the first half of 2022[23]. - The company submitted 73 applications for the National Natural Science Foundation and 14 projects were approved by the Shaanxi Provincial Department of Science and Technology in the first half of 2022[23]. - The company aims to build a leading health management group providing full lifecycle medical health services, focusing on expanding its business scale and enhancing core competitiveness[18]. Strategic Initiatives - The company is actively promoting the establishment of a new medical alliance network, expanding its medical service business scale by collaborating with over 100 grassroots medical institutions in Shaanxi Province[34]. - The company is developing a diversified specialty department sector, including neurology, oncology, and rehabilitation, to meet the growing healthcare demands of the community[33]. - The company is enhancing its internet medical network, integrating online and offline services to improve patient experience and extend its service reach into the internet healthcare market[35]. - The company is focused on innovative operational models, leveraging over 20 years of experience in managing large-scale tertiary hospitals to enhance service efficiency[31]. - The company is advancing its research and development in new medical technologies and services, including IVF capabilities, aiming to become one of the largest reproductive medicine centers in China[33]. - The company is exploring acquisition opportunities to enhance its service offerings and market share[103]. Environmental and Social Responsibility - The company reported no exceedances of environmental discharge standards in the first half of 2022[87]. - The company has implemented a new wastewater treatment system at the Shanzhou International Medical Center, which includes three-stage sedimentation and disinfection processes[85]. - The company emphasizes environmental protection and has taken measures to reduce carbon emissions, although specific measures were not detailed[87]. - The company has engaged in social responsibility initiatives, promoting environmental protection and participating in community welfare activities[88]. - In the first half of 2022, Xi'an International Medical Center Hospital organized 23 free clinics, benefiting approximately 3,100 individuals[90]. - The Sunshine Charity Fund provided nearly 1.7 million yuan in medical assistance to 270 impoverished patients in the first half of 2022[92]. Governance and Compliance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[94]. - The company has not provided any illegal external guarantees during the reporting period[94]. - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[93]. - The company reported no significant related party transactions during the reporting period[100]. - The company has not experienced any court judgments or significant debt defaults during the reporting period[99]. - The company has not undergone any management or operational changes during the reporting period[98]. - The company has not reported any significant penalties or corrective actions taken against it during the reporting period[97]. Future Outlook - The company has outlined a future outlook that includes potential market expansions and strategic partnerships to enhance its competitive edge[108]. - The company is committed to ongoing research and development of new medical technologies to improve patient care[113]. - The company has established a robust pipeline for future projects, indicating a commitment to long-term growth[105]. - The company is focused on expanding its market presence and developing new technologies, although specific details were not disclosed in the reports[110].

Financial Performance - The company's operating revenue for Q1 2022 was ¥304,865,465.75, a decrease of 51.78% compared to ¥632,244,259.12 in the same period last year[2] - The net profit attributable to shareholders was -¥428,421,595.49, representing a decline of 134.01% from -¥183,074,645.82 year-on-year[2] - The net cash flow from operating activities was -¥206,292,285.65, a significant decrease of 410.92% compared to ¥66,349,139.44 in the previous year[2] - Total operating revenue for Q1 2022 was CNY 304,865,465.75, a decrease of 51.8% compared to CNY 632,244,259.12 in the same period last year[13] - Net loss for Q1 2022 was CNY 432,820,830.09, compared to a net loss of CNY 185,159,657.65 in Q1 2021, indicating a significant increase in losses[14] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.1882, compared to CNY -0.0950 in the same period last year[15] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,888,019,415.82, down 3.25% from ¥13,320,275,545.21 at the end of the previous year[2] - The total assets decreased to CNY 12,888,019,415.82 from CNY 13,320,275,545.11 year-on-year[12] - The company's total liabilities decreased to CNY 7,938,186,655.74 from CNY 7,988,793,342.79 in the previous quarter[12] - The equity attributable to shareholders decreased by 7.08% to ¥4,948,267,140.76 from ¥5,325,517,348.40 at the end of the previous year[2] Cash Flow - The company's cash and cash equivalents decreased to ¥875,238,476.85 from ¥1,519,625,597.33, representing a decline of approximately 42.4%[10] - Cash inflow from investment activities totaled 395,951,934.84 RMB, down from 962,954,430.30 RMB in the prior period[17] - The net cash flow from financing activities was -27,939,026.41 RMB, compared to a positive 1,264,919,771.87 RMB in the previous period[17] - The total cash and cash equivalents at the end of the period were 875,238,476.85 RMB, down from 1,738,754,303.66 RMB at the beginning of the period[18] - The total cash outflow from operating activities was 573,267,605.86 RMB, slightly decreased from 585,782,097.73 RMB in the prior period[17] Operational Changes - The company reported a 51.78% decrease in operating revenue primarily due to the suspension of operations at subsidiaries Xi'an International Medical Center and Xi'an High-tech Hospital[4] - The company signed a framework agreement to transfer 99% equity of Shangluo International Medical Center Hospital, indicating a strategic move towards divestment[9] - The company’s stock was placed under risk warning and renamed to "ST Guoyi" due to operational disruptions, with a trading limit of 5%[8] - The company’s stock risk warning was lifted on April 18, 2022, allowing for a trading limit increase to 10%[9] Expenses - The company experienced a 30.09% increase in financial expenses, mainly due to interest expenses from its subsidiary[4] - Total operating costs for Q1 2022 were CNY 719,638,761.44, slightly down from CNY 742,690,177.83 year-on-year[13] - Research and development expenses for Q1 2022 were CNY 2,358,282.37, a slight decrease from CNY 2,593,910.77 in the previous year[13] - The company reported a significant increase in tax expenses, totaling CNY 7,047,554.79 in Q1 2022, compared to CNY 4,678,301.98 in Q1 2021[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 136,877, with the largest shareholder holding 29.74% of the shares[5] Audit Information - The company did not conduct an audit for the first quarter report[18]

Financial Performance - The company's operating revenue for 2021 was CNY 2,921,127,110.49, representing an increase of 81.78% compared to CNY 1,606,986,016.51 in 2020[13]. - The net profit attributable to shareholders was -822,169,217.83 CNY, a decrease of 1,912.52% compared to the previous year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -751,278,828.82 CNY, a decrease of 15.85% year-on-year[14]. - The operating cash flow net amount was 456,338,668.29 CNY, an increase of 1,004.15% compared to the previous year[14]. - Total assets at the end of 2021 were 13,320,275,545.11 CNY, an increase of 9.86% from the end of 2020[14]. - The net assets attributable to shareholders at the end of 2021 were 5,325,517,348.40 CNY, an increase of 6.49% from the end of 2020[14]. - The basic earnings per share were -0.37 CNY, a decrease of 1,950.00% compared to the previous year[14]. - The diluted earnings per share were also -0.37 CNY, reflecting the same percentage decrease[14]. - The company reported total operating revenue of 2,921,127,110.49 CNY for 2021, compared to 1,606,986,016.51 CNY in 2020[15]. - The operating revenue after deductions was 2,892,438,757.95 CNY, up from 1,592,998,771.65 CNY in the previous year[15]. Business Strategy and Transformation - The company has undergone a strategic transformation since 2018, focusing on health services and modern medical technology applications after divesting its retail business[10]. - The company’s main business has shifted to health services and modern medical technology since acquiring Xi'an Gaoxin Hospital in 2011[10]. - The company has not made any changes to its major business operations since its listing in 1993, maintaining a focus on retail until the strategic shift in 2018[10]. - The company aims to implement a "medical + health" service model, integrating online and offline services, and promoting cutting-edge medical technologies like stem cell applications[67]. - The company is actively expanding its international cooperation with renowned medical institutions in the US, UK, Japan, Germany, and South Korea[28]. Market and Demand Insights - The healthcare service demand in China is characterized by significant rigidity, with a growth rate of medical service demand significantly outpacing the growth of medical resources supply[21]. - The chronic disease prevalence rate in China has reached 23%, with nearly double the number of new chronic cases added annually over the past decade, highlighting a growing demand for medical services[21]. - The aging population and increasing health awareness among residents are driving a shift towards proactive healthcare services, further boosting the demand for the company's offerings[21]. - The implementation of the "three-child" policy is expected to increase the demand for assisted reproductive services in the future[22]. - The demand for rehabilitation medical services is expected to rise, supported by new government policies aimed at enhancing the rehabilitation healthcare system[22]. Operational Performance - In the reporting period, the outpatient and emergency visits reached 1.8098 million, a year-on-year increase of 36.10%, while inpatient admissions totaled 122,600, up 64.24%[24]. - The company has established a high-level comprehensive medical platform with nearly 10,000 beds, enhancing its service capacity and operational performance[24]. - The company launched an equity incentive plan, granting 35,279,116 restricted shares to 544 core medical staff and management team members to drive growth[24]. - The company is expanding its specialty services, including advanced fields like oncology, cardiology, and reproductive medicine, with plans to become a leading reproductive medicine center in China[25]. - The company has signed agreements with over 60 grassroots medical institutions in Shaanxi province to expand its medical service network and improve access to quality healthcare[25]. Governance and Compliance - The company has established a complete modern enterprise system, ensuring good operational management despite risks from medical service development limitations and individual patient differences[76]. - The company adheres to legal regulations and continuously improves its corporate governance structure, ensuring compliance with relevant laws and regulations[79]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a fair and independent decision-making process[80]. - The company has implemented performance evaluation and incentive mechanisms for its management, linking compensation and promotions to performance metrics[80]. - The company has established an internal audit system and appointed a responsible person to ensure effective internal control over daily operations[81]. Environmental and Social Responsibility - The company’s environmental management includes compliance with pollution discharge standards, with no exceedances reported for major pollutants[130]. - The hospital under the company has six organized emission outlets for sulfur dioxide, particulate matter, and nitrogen oxides, all meeting the required discharge standards[130]. - The company actively fulfills social responsibilities, protecting the rights of shareholders, employees, suppliers, and patients while promoting environmental protection initiatives[136]. - The company has established a complete human resources management system and social insurance management system to protect employee rights and ensure timely salary payments[136]. - The company has committed to a 36-month lock-up period for shares obtained through non-public issuance, ensuring compliance with regulatory requirements[138]. Future Outlook and Guidance - The company aims to enhance its operational efficiency and profitability through strategic mergers and acquisitions in the healthcare sector[93]. - Future guidance indicates a continued focus on revenue growth, targeting a year-on-year increase of at least 20% in the upcoming fiscal year[93]. - The company has set a revenue guidance of 6,500 million for 2022, representing a 17% growth target[158]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 25% increase in market presence by 2023[158]. - The company plans to launch three new medical products in 2022, aiming to capture a larger market share[158].